December 1st 2023
This new data adds to the growing body of literature regarding the benefits and risks of prescribing isotretinoin for dermatology patients.
November 28th 2023
November 28th 2023
November 26th 2023
November 26th 2023
The 5th Annual Advanced Practice Collaborative™
View More
Collaborating Across the Continuum™ : Managing Relapsing MS – A Focus on the Utility of CD20-Targeted B-Cell Therapy
View More
4th annual Precision Medicine Symposium: An Illustrated Tumor Board
View More
Clinical Consultations™: Raising Awareness and Optimizing Treatment in Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)
View More
Medical Crossfire®: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
View More
Addressing Healthcare Inequities: Overcoming Challenges in the Equitable Management of Idiopathic Pulmonary Fibrosis
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Gastrointestinal Malignancies from Paris
View More
FDA Accepts Xanomeline-Trospium Drug Application for Schizophrenia Treatment
November 29th 2023The FDA will decide on the approval of xanomeline-trospium, a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, for the treatment of schizophrenia patients by September 2024.